More Widespread use of Ivermectin for the Treatment of COVID-19 Infection could have Saved Many

Abstract

Abstract: Here we review the available literature for the specific use of Ivermectin against COVID-19 infection. Currently, 204 works have been published presenting the results of ivermectin use for COVID-19. 156 are peer-reviewed, and 96 are comparing treatment and control groups. Ivermectin was adopted for early treatment in all or part of 22 countries (39 including non-government medical organizations). The 96 studies of Ivermectin for COVID-19 were published by 1,030 scientists, reporting the cases of 135,554 patients in 27 countries. These studies show a statistically significant improvement in mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance. Specifically, improvements recorded were 85%, 62%, and 43% for prophylaxis, early, and late treatment, with confidence intervals (CI) [77-90%], [51-70%], [28-54%] respectively. A 56% improvement was recorded in the 45 randomized controlled trials (RCTs) with CI [41-68%]. A 51% lower mortality was evidenced from 49 studies with CI [37-61%]. In February 2021, when the war on Ivermectin started in the West, it was clear that this drug had positive effects, working in-vivo/in-vitro, and delivering mostly positive results in clinical trials. More widespread use of Ivermectin could have saved many people, and suppression of this drug in many countries that had very high cumulative fatalities per million people has been a very unfortunate occurrence for science.